- Home
- SMSI vs LYRA Comparison
SMSI vs LYRA Comparison
Compare SMSI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- LYRA
- Stock Information
- Founded
- SMSI 1982
- LYRA 2005
- Country
- SMSI United States
- LYRA United States
- Employees
- SMSI N/A
- LYRA N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- LYRA Medical/Dental Instruments
- Sector
- SMSI Technology
- LYRA Health Care
- Exchange
- SMSI Nasdaq
- LYRA Nasdaq
- Market Cap
- SMSI 16.2M
- LYRA 13.5M
- IPO Year
- SMSI 1995
- LYRA 2020
- Fundamental
- Price
- SMSI $1.13
- LYRA $0.19
- Analyst Decision
- SMSI Strong Buy
- LYRA Buy
- Analyst Count
- SMSI 1
- LYRA 5
- Target Price
- SMSI $5.00
- LYRA $4.50
- AVG Volume (30 Days)
- SMSI 732.1K
- LYRA 1.9M
- Earning Date
- SMSI 02-20-2025
- LYRA 11-12-2024
- Dividend Yield
- SMSI N/A
- LYRA N/A
- EPS Growth
- SMSI N/A
- LYRA N/A
- EPS
- SMSI N/A
- LYRA N/A
- Revenue
- SMSI $24,178,000.00
- LYRA $1,471,000.00
- Revenue This Year
- SMSI N/A
- LYRA N/A
- Revenue Next Year
- SMSI $53.43
- LYRA N/A
- P/E Ratio
- SMSI N/A
- LYRA N/A
- Revenue Growth
- SMSI N/A
- LYRA 3.37
- 52 Week Low
- SMSI $0.52
- LYRA $0.16
- 52 Week High
- SMSI $7.52
- LYRA $6.79
- Technical
- Relative Strength Index (RSI)
- SMSI 47.52
- LYRA 46.20
- Support Level
- SMSI $1.05
- LYRA $0.18
- Resistance Level
- SMSI $1.95
- LYRA $0.22
- Average True Range (ATR)
- SMSI 0.23
- LYRA 0.02
- MACD
- SMSI -0.06
- LYRA -0.00
- Stochastic Oscillator
- SMSI 8.89
- LYRA 16.31
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. It offers multi-platform, modular solutions such as SafePath; CommSuite; and ViewSpot. The company's only reportable segment is Wireless. Its Wireless segment sells to large wireless carriers, cable operators, and OEMs.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.